Success Story: A Chinese Equity Research Associate Secures Dual NIW and EB1A Approvals with Our Support

Client’s Testimonial:

“I am incredibly grateful for the exceptional support and guidance I received from Chen Immigration throughout my Dual NIW and EB1A green card application process. Their expertise, meticulous attention to detail, and unwavering patience made navigating the complexities of immigration law much smoother. Chen Immigration took the time to explain each step, addressed all my concerns thoughtfully, and made me feel genuinely supported from start to finish. Thanks to their dedication and professionalism, my application was successful, and I highly recommend Chen Immigration to anyone seeking reliable and compassionate legal assistance.”

On September 20^th, 2023, and March 27^th, 2025, we received another EB-2 NIW (National Interest Waiver) and EB-1A (Alien of Extraordinary Ability) approvals for an Equity Research Associate in the Field of Cell Biology (Approval Notice).

General Field: Cell Biology

Position at the Time of Case Filing: Equity Research Associate

Country of Origin: China

State of Residence at the Time of Filing: New York

Approval Notice Date: : September 20^th, 2023 (NIW) and March 27^th, 2025 (EB1A)

Processing Time: 2 months, 29 days (NIW), and 13 months, 19 days (EB1A)

Case Summary:   

We are pleased to announce the I-140 approvals under both the National Interest Waiver (NIW) and EB1A categories for an accomplished cell biologist originally from China. The NIW petition was approved in September 2023, and the EB1A was approved in March 2025 following a detailed final merits review. Together, these approvals affirm the petitioner’s extraordinary ability and her significant impact on U.S. biomedical research.

Driving Scientific Innovation in Cellular Signal Transduction

Holding a Ph.D. in biological sciences, the petitioner is recognized for her original and influential research in signal transduction and programmed cell death (apoptosis). Her work sheds light on mechanisms that regulate cholesterol uptake, cellular stress response, and cancer therapy targets, areas that directly impact cardiovascular health, oncology, and circadian biology.

Currently employed in a U.S.-based research and analysis role, she continues to study molecular mechanisms of disease progression and treatment innovation.

Recognized Contributions and Scientific Authority

At the time of filing, the petitioner had published 8 peer-reviewed journal articles, including work in high-impact journals. Her work has been cited 425 times, with three of her papers ranking among the top 10% most cited in Biology & Biochemistry for their year. She has also completed at least 10 verified peer reviews and serves on the editorial board of a leading journal in cell biology.

Her research has been directly cited by investigators at over 40 academic institutions in North America, Europe, and Asia, evidence of its global scientific value and relevance.

Expert Endorsements from International Leaders

The petition was supported by four letters of recommendation from respected scientists, including two independent experts from the United Kingdom and the United States. These letters confirmed the petitioner’s major contributions and her status as a leading voice in apoptosis and signal transduction research.

“Furthermore, her work elucidating the role of cellular processes in diseases like cancer is of the utmost importance to humanity at large. Taking all of this information into consideration, the United States cannot afford to lose a scientist of [Client’s] caliber.”

Through cutting-edge research, substantial peer recognition, and global citation impact, the petitioner has demonstrated a lasting influence on the field of cell biology. Her EB1A and NIW approvals reflect her continued potential to advance biomedical innovation in the United States.